Success Metrics

Active Trials
2(40%)

Phase Distribution

Ph phase_3
1
20%
Ph not_applicable
2
40%
Ph phase_2
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Other(2)

Detailed Status

unknown2
Recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 31 (20.0%)
N/A2 (40.0%)

Trials by Status

unknown240%
not_yet_recruiting120%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

NCT06964568
recruitingphase_2

Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07055841
not_yet_recruitingnot_applicable

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

NCT06649448
unknownphase_2

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer

NCT04499118
unknownnot_applicable

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients

NCT01393080

Clinical Trials (5)

Showing 5 of 5 trials
NCT06964568Phase 3

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

Recruiting
NCT07055841Phase 2

Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
NCT06649448Not Applicable

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not Yet Recruiting
NCT04499118Phase 2

AT Versus TP as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer

Unknown
NCT01393080Not Applicable

Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5